Genomac was founded in 2001 by Marek Minarik and Lucie Benesova (born Minarikova) primarily as a contract DNA sequencing and genotyping company. In 2003 company relocated from its founding site in Prague’s Brevnov residential district into Prague 5 industrial area and has announced launch of DNA paternity testing services along with preventive testing of genetic syndrommes including Cystic fibrosis, thrombophilia, phenylkenotonuria, hypercholosterolemia, hemochromatosis and others. Between 2006 and 2007 Genomac has introduced a family of genetic genealogy tests and by the end of 2007 more than a thousand of Genograf® DNA ancestry tests has been performed. The enormous success has prompted foundation of the Czech National Genographic Database, containing voluntary submissions of DNA ancestry profiles from more than 7,000 individuals. A whole new portfolio of commercial DNA-based products and services has been launched between 2010 and 2011. A DNA-based art in forms of genetic portraits (Genoportrait®) and DNA-based genetic jewelry (Genoklenot®) has captured interest of wide public. In addition a DNA testing of genetic traits Genoskop has been introduced within the newly established field of “recreational genetics”.
In 2007 Genomac has received a certification as an official forensic expert institute for the field of genetics and DNA analysis by the Czech Ministry of Justice. Along with successful commercial activities, Genomac has developed original technology for the detection of DNA mutations and polymorphisms. In 2004, Genomac was awarded a research grant by the Czech Ministry of Heath aimed at genetic predisposition to prostate cancer and at improvement of sensitivity in molecular diagnostics of pancreatic cancer. A paper on KRAS testing along with APC and TP53 in colorectal tissue has been published later that year. In 2006, a US Patent No. 6,989,085 covering Genomac technology for mutation detection under partial denaturing conditions as awarded. Genomac has continuously been active in applied clinical science, predominantly in molecular cancer research directed at gastrointestinal tumors (cancers of stomach, pancreas, colon and rectum) as well as lung cancer. In 2005, Genomac has introduced a routine testing of EGFR mutations from lung tissue in prediction of response to targeted biological therapy of non-small cell lung cancer (NSCLC). In addition, clinical significance was also reached by successful projects in cardiovascular research directed at Hypertrophic cardiomyopathy and pharmacotherapy of coronary artery disease. In 2009 Genomac has demonstrated applicability of its technology to detection of cell-free tumor DNA in cancer patients. In subsequent years, cell-free tumor DNA (better known as circulating-tumor DNA, ctDNA) detection has been a centerpoint of research at Genomac.
In 2010, a project funds appointed to Genomac by the city of Prague within the EU funding programs (Prague Operational Programme, OPPK CZ.2.16/3.1.00/22213) has prompted establishment of a Center for Applied Genomics of Solid Tumors (CEGES) representing a new era for Genomac further stimulated by relocation to newly constructed 450m2 facility near Prague’s Vaclav Havel airport in Ruzyne. At that point all research and development activities have formally come together under the label of Genomac Research Institute. The CEGES project has further been extended in 2014 (Prague Operational Programme, OPPK CZ.2.16/3.3.00/22558). In total by 2015, Genomac was awarded 15 research grants in cancer and cardiovascular research by various government bodies. At the same time Genomac’s scientific activity resulted in publication of a total of 42 research articles (with impact factor).